The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.

Regardless of their hepatitis B e antigen (HBeAg) status, these patients had a lower median HBV DNA level than did those with persistently or intermittently elevated serum ALT levels and a lower ...

Hepatitis B virus (HBV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death globally.1,2 The highest prevalence is found in low-income and middle-income countries ...